ATE220894T1 - Zusammensetzung für lokale freigabe von zytostatika - Google Patents

Zusammensetzung für lokale freigabe von zytostatika

Info

Publication number
ATE220894T1
ATE220894T1 AT95905986T AT95905986T ATE220894T1 AT E220894 T1 ATE220894 T1 AT E220894T1 AT 95905986 T AT95905986 T AT 95905986T AT 95905986 T AT95905986 T AT 95905986T AT E220894 T1 ATE220894 T1 AT E220894T1
Authority
AT
Austria
Prior art keywords
composition
cytostatics
local release
cytostatic agent
methods
Prior art date
Application number
AT95905986T
Other languages
English (en)
Inventor
Dennis M Brown
Richard E Jones
Richard Maskiewicz
Shawnya K Michaels
Original Assignee
Matrix Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matrix Pharma filed Critical Matrix Pharma
Application granted granted Critical
Publication of ATE220894T1 publication Critical patent/ATE220894T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT95905986T 1993-12-29 1994-12-28 Zusammensetzung für lokale freigabe von zytostatika ATE220894T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17515693A 1993-12-29 1993-12-29
PCT/US1994/014559 WO1995017901A1 (en) 1993-12-29 1994-12-28 Methods and compositions for the treatment of a host with a cellular proliferative disease

Publications (1)

Publication Number Publication Date
ATE220894T1 true ATE220894T1 (de) 2002-08-15

Family

ID=22639161

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95905986T ATE220894T1 (de) 1993-12-29 1994-12-28 Zusammensetzung für lokale freigabe von zytostatika

Country Status (8)

Country Link
US (1) US5573781A (de)
EP (1) EP0739210B1 (de)
JP (1) JPH09507233A (de)
AT (1) ATE220894T1 (de)
AU (1) AU681231B2 (de)
CA (1) CA2180260A1 (de)
DE (1) DE69431071T2 (de)
WO (1) WO1995017901A1 (de)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5935967A (en) * 1995-06-05 1999-08-10 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of highly lipophilic camptothecin derivatives
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
EP1006935B1 (de) * 1995-06-07 2005-01-26 Southern Biosystems, Inc. Kontrolliertes zuführsystem mit einer flüssigkeit von hoher viskosität
US5968542A (en) * 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
DE69734060T2 (de) 1996-05-24 2006-06-29 Angiotech Pharmaceuticals, Inc., Vancouver Zubereitungen und verfahren zur behandlung oder prävention von krankheiten der körperpassagewege
US5773461A (en) * 1996-06-06 1998-06-30 Bristol-Myers Squibb Company 7-deoxy-6-substituted paclitaxels
NZ334236A (en) * 1996-08-30 2000-06-23 Peptech Ltd Composition comprising GnRH, lecithin and stearin
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US20030157187A1 (en) * 1996-12-02 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory diseases
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6630168B1 (en) * 1997-02-20 2003-10-07 Biomedicines, Inc. Gel delivery vehicles for anticellular proliferative agents
BR9809064A (pt) 1997-04-03 2002-01-02 Guilford Pharm Inc Polìmeros biodegradáveis de poliéster de tereftalato-polifosfato, composições, artigos e métodos para fazer e usar os mesmos
US6416740B1 (en) 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
US6485514B1 (en) 1997-12-12 2002-11-26 Supergen, Inc. Local delivery of therapeutic agents
GB9803448D0 (en) * 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
US7030155B2 (en) * 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
AUPP466598A0 (en) * 1998-07-14 1998-08-06 University Of Newcastle Research Associates Limited, The Product and process
US6419709B1 (en) 1998-10-02 2002-07-16 Guilford Pharmaceuticals, Inc. Biodegradable terephthalate polyester-poly(Phosphite) compositions, articles, and methods of using the same
US6153212A (en) * 1998-10-02 2000-11-28 Guilford Pharmaceuticals Inc. Biodegradable terephthalate polyester-poly (phosphonate) compositions, articles, and methods of using the same
US6350464B1 (en) 1999-01-11 2002-02-26 Guilford Pharmaceuticals, Inc. Methods for treating ovarian cancer, poly (phosphoester) compositions, and biodegradable articles for same
CA2369739C (en) * 1999-02-23 2008-12-16 Angiotech Pharmaceuticals, Inc. Compositions and methods for improving integrity of compromised body passageways and cavities
US6537585B1 (en) 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
US6767926B1 (en) * 1999-10-12 2004-07-27 Temple University - Of The Commonwealth System Of Higher Education Method for protecting normal cells from cytotoxicity of chemotherapeutic agents
CZ302498B6 (cs) * 1999-11-15 2011-06-15 Pharma Mar, S. A. Farmaceutický prípravek obsahující aplidin pro lécení rakovinových onemocnení
DE60229414D1 (de) * 2001-10-19 2008-11-27 Pharma Mar Sa Verwendung von aplidine in der behandlung von pankreaskrebs
DE60221287D1 (de) * 2001-11-08 2007-08-30 Atrium Medical Corp Intraluminale vorrichtung mit einer ein therapeutisches-mittel enthaltenden beschichtung
EP1453468A4 (de) * 2001-11-09 2005-11-23 Chiron Corp Verfahren zur impfung eines menschlichen patienten zur verhinderung von tumormetastasen
US6977247B2 (en) * 2002-02-21 2005-12-20 Supergen, Inc. Sequential therapy comprising a 20(S)-camptothecin and a pyrimidine base analog
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
US7544674B2 (en) 2002-10-25 2009-06-09 Galderma S.A. Topical skin care composition
ATE482695T1 (de) 2002-12-13 2010-10-15 Durect Corp Orale darreichungsform mit flüssigen hochviskosen trägersystemen
AU2004218883B2 (en) * 2003-03-12 2009-10-01 Dana-Farber Cancer Institute, Inc. Aplidine for multiple myeloma treatment
US20040265351A1 (en) * 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
US20070140999A1 (en) * 2003-07-18 2007-06-21 Hill Dermaceuticals, Inc. Topical skin care composition containing refined peanut oil
WO2005009406A1 (en) * 2003-07-18 2005-02-03 Hill Dermaceuticals, Inc. Topical skin care composition containing refined peanut oil
US20060099173A1 (en) * 2003-10-24 2006-05-11 Nancy Puglia Topical skin care composition
US20050118206A1 (en) * 2003-11-14 2005-06-02 Luk Andrew S. Surfactant-based gel as an injectable, sustained drug delivery vehicle
US20050208095A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
AU2005287175B2 (en) 2004-09-17 2011-12-01 Durect Corporation Sustained local anesthetic composition containing preferably a sugar ester such as SAIB
US9000040B2 (en) 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
EP1811935B1 (de) 2004-09-28 2016-03-30 Atrium Medical Corporation Wärmegehärtetes gel und herstellungsverfahren
US9012506B2 (en) 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US20060141040A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US9278161B2 (en) 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
US9427423B2 (en) 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
US20090197975A1 (en) * 2005-12-23 2009-08-06 Miv Therapeutics Inc. Compositions formulated for solvent-regulated drug release
US8337883B2 (en) 2006-11-03 2012-12-25 Durect Corporation Transdermal delivery systems
EP2219622A1 (de) 2007-12-06 2010-08-25 Durect Corporation Verfahren zur behandlung von schmerzen, arthritischen zuständen oder entzündung im zusammenhang mit einer chronischen erkrankung
EP2271214B1 (de) * 2008-03-28 2017-05-03 Particle Sciences, Inc. Pharmazeutische lösungen und verfahren zur auflösung von therapeutika
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
US20110038910A1 (en) 2009-08-11 2011-02-17 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
US10842770B2 (en) 2010-05-03 2020-11-24 Teikoku Pharma Usa, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
US10322213B2 (en) 2010-07-16 2019-06-18 Atrium Medical Corporation Compositions and methods for altering the rate of hydrolysis of cured oil-based materials
US9867880B2 (en) 2012-06-13 2018-01-16 Atrium Medical Corporation Cured oil-hydrogel biomaterial compositions for controlled drug delivery
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
TW201427681A (zh) * 2013-01-07 2014-07-16 Superlab Far East Ltd 用空間構象改變的重組干擾素治療腫瘤的方法
TW201521769A (zh) 2013-03-15 2015-06-16 Durect Corp 具有流變改質劑以減少溶解變異性之組成物
WO2014179528A2 (en) * 2013-05-01 2014-11-06 Brown Dennis M Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted naphthalimides such as amonafide for the treatment of immunological, metabolic, infectious, and benign or neoplastic hyperproliferative disease conditions
CN112472699A (zh) 2013-07-26 2021-03-12 种族肿瘤学公司 改善比生群及衍生物的治疗益处的组合方法
EP3079668A1 (de) 2013-12-09 2016-10-19 Durect Corporation Pharmazeutisch aktive wirkstoffkomplexe, polymerkomplexe und zusammensetzungen und verfahren damit
SG11201811760VA (en) 2016-07-06 2019-01-30 Durect Corp Oral dosage form with drug composition, barrier layer and drug layer
WO2018144094A1 (en) * 2016-11-03 2018-08-09 Health Research, Inc. Methods for improving tumor chemotherapy
KR20210078505A (ko) 2018-10-16 2021-06-28 유에스 나노 푸드 앤 드럭 인코포레이티드 종양내 주사 제형
CN115666621A (zh) 2020-01-13 2023-01-31 度勒科特公司 具有减少的杂质的持续释放药物递送系统及相关方法
WO2021211294A1 (en) * 2020-04-13 2021-10-21 US Nano Food & Drug INC Basic chemotherapeutic intratumour injection formulation
KR20230131815A (ko) * 2020-08-19 2023-09-14 셀액트 파마 게엠베하 에토포시드 토니리베이트 제제
CA3203561A1 (en) 2021-01-12 2022-07-21 Adrian Neil Verity Sustained release drug delivery systems and related methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6317823A (ja) * 1986-07-10 1988-01-25 Mitsubishi Chem Ind Ltd 抗固形腫瘍剤
US4879297A (en) * 1987-06-01 1989-11-07 Warner-Lambert Company Fatty acids and their small chain esters as penetration enhancers in aqueous systems
JPH01156990A (ja) * 1987-09-26 1989-06-20 Ajinomoto Co Inc 新規白金錯体及びその用途
US5141751A (en) * 1988-06-29 1992-08-25 Daiichi Pharmaceutical Co., Ltd. Lipid membrane structures
US5015257A (en) * 1989-03-20 1991-05-14 Zimmer, Inc. Prosthetic interpositional device/coupler
US5051257A (en) * 1989-05-09 1991-09-24 Pietronigro Dennis D Antineoplastic solution and method for treating neoplasms
FI905018A7 (fi) * 1989-10-17 1991-04-18 Bristol Myers Squibb Co Veteen ja liuottimeen liukenevat aksiaaliset hydroksi- ja mono- ja di-karboksyylihappojohdannaiset, joilla on korkea kasvainaktiivisuus
US5143934A (en) * 1990-11-21 1992-09-01 A/S Dumex (Dumex Ltd.) Method and composition for controlled delivery of biologically active agents

Also Published As

Publication number Publication date
AU681231B2 (en) 1997-08-21
DE69431071T2 (de) 2003-03-20
CA2180260A1 (en) 1995-07-06
JPH09507233A (ja) 1997-07-22
EP0739210A1 (de) 1996-10-30
DE69431071D1 (de) 2002-08-29
US5573781A (en) 1996-11-12
EP0739210B1 (de) 2002-07-24
WO1995017901A1 (en) 1995-07-06
AU1438695A (en) 1995-07-17
EP0739210A4 (de) 1997-10-15

Similar Documents

Publication Publication Date Title
DE69431071D1 (de) Zusammensetzung für lokale freigabe von zytostatika
ES2553184T3 (es) Colagenasa para tratar la celulitis
UA29406C2 (uk) Складні ефіри трициклічних аміноспиртів
ES2190472T3 (es) Parche transdermico para la administracion de 17-deacetil norgestimato, solo o en combinacion con un estrogeno.
ES2075011T3 (es) Uso de sales del acido gamma-hidroxibutirico para preparar composiciones farmaceuticas para uso en el tratamiento del alcoholismo, y las composiciones obtenidas.
BR0206984A (pt) Composições de depósito injetáveis e uso destas
AR004483A1 (es) Compuestos para uso en terapia que comprenden un residuo de 1,3-propano diol como agente enlazante entre el residuo de ácido graso y un residuo bioactivo, usos de dichos compuestos y medicamentos , alimentos y formulaciones para el cuidado o tratamiento de la piel que comprenden a dichos compuestos
ES2039278T3 (es) Procedimiento para preparar inhibidores de 5-alfa-reductasa de esteroides.
ATE205723T1 (de) Applikation von sod in liposomen
NO20051029L (no) Injiserbare depotpreparater og anvendelser derav
ES2173978T3 (es) Utilizacion de un alcohol graso insaturado.
MX9504955A (es) Composiciones cosmeticas para el autobronceado de la piel, a base de dihidroxiacetona, alquilpoliglucosidos y alcoholes grasos.
AR018357A1 (es) Acido petroselinico en una composicion y en un metodo para reducir o eliminar la irritacion o la picazon de la piel inducida por los alfa-hidroxiacidos
MX9206309A (es) Metodo y composicion para tratar tumores que tienen alta actividad de tirosinasa.
DK0462194T3 (da) Fibroblastvækstfaktor-(FGF)-baserede stabiliserede sammensætninger
BRPI0418070A (pt) composição para cuidados pessoais, uso de uma uréia substituìda e método para reduzir a degradação da cor de uma composição para cuidados pessoais
GB9413873D0 (en) Long-acting oxytetracycline composition
EA200700044A1 (ru) Композиция для местного применения
MX9207150A (es) Metodo y composiciones para reducir la resistenciaa multiples farmacos.
BR0107544A (pt) Composição de promoção de secreção de bile
ES2128417T3 (es) Formulacion y utilizacion de carotenoides en el tratamiento del cancer.
ATE345777T1 (de) Biologisch aktive zusammensetzung
ES2042529T3 (es) Un procedimiento para preparar una composicion terapeutica combinada de un eliminador de radicales libres o inhibidor metabolico y una proteina biologicamente activa.
CO4970834A1 (es) Composiciones que contienen combinaciones de poliesteres de acidos grasos de poliol solidos y un aceite solido
IE790098L (en) Solvent vehicle

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties